Stryker Corporation (SYK) VP Sells $214,732.52 in Stock

Stryker Corporation (NYSE:SYK) VP William E. Berry, Jr. sold 1,306 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total value of $214,732.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Stryker Corporation (SYK) traded up $0.63 during midday trading on Thursday, reaching $156.87. The company had a trading volume of 179,550 shares, compared to its average volume of 1,439,483. Stryker Corporation has a 12-month low of $124.89 and a 12-month high of $170.00. The stock has a market cap of $57,904.67, a P/E ratio of 58.30, a P/E/G ratio of 2.22 and a beta of 0.70. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The firm had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period last year, the business posted $1.78 EPS. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis. equities research analysts anticipate that Stryker Corporation will post 7.12 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 1.20%. The ex-dividend date is Wednesday, March 28th. Stryker’s payout ratio is currently 70.15%.

A number of analysts have weighed in on SYK shares. Wells Fargo & Co increased their price objective on Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. SunTrust Banks reaffirmed a “buy” rating and set a $161.00 price objective on shares of Stryker in a research report on Friday, November 17th. Cowen set a $166.00 price objective on Stryker and gave the stock a “buy” rating in a research report on Sunday, October 29th. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Finally, Canaccord Genuity raised their price target on Stryker from $155.00 to $162.00 and gave the company a “buy” rating in a report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $162.50.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Truewealth LLC purchased a new position in Stryker during the fourth quarter worth $110,000. Acrospire Investment Management LLC purchased a new position in Stryker during the second quarter worth $111,000. Sawyer & Company Inc purchased a new position in Stryker during the fourth quarter worth $125,000. Sit Investment Associates Inc. increased its position in Stryker by 114.3% during the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock worth $128,000 after buying an additional 440 shares in the last quarter. Finally, Virtue Capital Management LLC purchased a new position in Stryker during the fourth quarter worth $133,000. 74.71% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Stryker Corporation (SYK) VP Sells $214,732.52 in Stock” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with's FREE daily email newsletter.

Leave a Reply